AYOONMEDI DERMA NEWS [08 - APRIL -2024]

Fixed-dose clindamycin phosphate 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1% gel have shown to achieve faster-acting efficacy compared to dyads and vehicle, as per a recent study led by dermatologist Julie C. Harper, MD, and colleagues. The study emphasizes the challenge of acne treatment due to its chronic nature and multifaceted underlying causes, often resulting in low adherence to therapy. Combination therapies, targeting various acne pathogenesis processes simultaneously, are recommended, with IDP-126 (Cabtreo, Bausch Health) being the first triple-combination gel approved for acne. Results from phase 2 and 3 double-blind studies involving over 1,100 patients demonstrate that IDP-126 not only provides rapid relief but also sustained clearance of acne lesions. By week 12, a significantly higher proportion of patients treated with IDP-126 achieved reduction in inflammatory lesions compared to those treated with dyads or vehicle. This fast-acting and effective feature of IDP-126, along with its once-a-day application and good tolerability, may improve treatment adherence.

As a concluding remark, the authors suggest that IDP-126 gel could be a desirable treatment option for patients with moderate to severe acne.